VIP gene variants related to idiopathic pulmonary arterial hypertension in Chinese population

Clinical Genetics

Volumn 75, Issue 6, 2009, Pages 544-549

  Zhang, Y ^a   Zhang, J Q ^a   Liu, Z H ^a   Xiong, C M ^a   Ni, X H ^a   Hui, R T ^b   He, Jian Guo ^a,b   Pu, Jie Lin ^a,b  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b FUWAI HOSPITAL   (China)

Author keywords

Enzyme linked immunosorbent assay; Genetics; Idiopathic pulmonary arterial hypertension; Vasoactive intestinal peptide

Indexed keywords

VASOACTIVE INTESTINAL POLYPEPTIDE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CHINESE; CLINICAL ASSESSMENT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXON; FEMALE; GENE SEQUENCE; GENETIC CODE; GENETIC SCREENING; GENETIC VARIABILITY; HEMODYNAMICS; HUMAN; IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION;

ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; CHINA; FEMALE; GENETIC VARIATION; HEMODYNAMICS; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; POINT MUTATION; PULMONARY ARTERY; SEQUENCE ANALYSIS, DNA; VASOACTIVE INTESTINAL PEPTIDE;

EID: 66549114437     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2009.01196.x     Document Type: Article

References (24)

1. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004: 351: 1655-1665.
2. Newman JH, Fanburg BL, Archer SL et al. Pulmonary arterial hypertension: future directions: Report of a National Heart, Lung and Blood Institute/ Office of Rare Diseases workshop. Circulation 2004: 109: 2947-2952.
3. Runo JR, Loyd JE. Primary pulmonary hypertension. Lancet 2003: 361: 1533-1544.
4. Said SI, Mutt V. Polypeptide with broad biological activity: Isolation from small intestine. Science 1970: 169: 1217-1218.
5. Hamasaki Y, Mojarad M, Said SI. Relaxant action of VIP on cat pulmonary artery: Comparison with acetylcholine, isoproterenol and PGE1. J Appl Physiol Respir Environ Exerc Physiol 1983: 54: 1607-1611.
6. Saga T, Said SI. Vasoactive intestinal peptide relaxes isolated strips of human bronchus, pulmonary artery, and lung parenchyma. Trans Assoc Am Physicians 1984: 97: 304-310.
7. Petkov V, Mosgoeller W, Ziesche R et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003: 111: 1339-1346.
8. Said SI, Hamidi SA, Dickman KG et al. Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation 2007: Mar 13: 115(10): 1260-1268.
9. Dey RD, Shimosegava T, Said SI. Lung peptides and the pulmonary circulation. In: Said SI, ed. The pulmonary circulation and acute lung injury. 2nd ed. Mount Kisco, NY: Futura Publishing Co, 1991: 137-175.
10. Simonneau G, Galie N, Rubin LJ et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004: 43: 5S-12S.
11. Haberl I, Frei K, Ramsebner R et al. Vasoactive intestinal peptide gene alterations in patients with idiopathic pulmonary arterial hypertension. Eur J Hum Genet 2007: 15(1): 18-22.
12. Cox CP, Linden J, Said SI. VIP elevates platelet cyclic AMP (cAMP) levels and inhibits in vitro platelet activation induced by platelet-activating factor (PAF). Peptides 1984: 5(2): 325-328.
13. Gagnon AW, Aiyar N, Elshourbagy NA. Molecular cloning and functional characterization of a human liver vasoactive intestinal peptide receptor. Cell Signal 1994: 6(3): 321-333.
14. Sreedharan SP, Robichon A, Peterson KE et al. Cloning and expression of the human vasoactive intestinal peptide receptor. Proc Natl Acad Sci U S A 1991: 88(11): 4986-4990.
15. Eddahibi S, Morrell N, d'Ortho MP et al. Pathobiology of pulmonary arterial hypertension. Eur Respir J 2002: 20(6): 1559-1572.
16. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 2006: 114(13): 1417-1431.
17. Atkinson C, Stewart S, Upton PD et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002: 105: 1672-1678.
18. Newman JH, Trembath RC, Morse JA et al. Genetic basis of pulmonary arterial hypertension: Current understanding and future directions. J Am Coll Cardiol 2004: 43: 33S-39S.
19. Deng Z, Morse JH, Slager SL et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000: 67(3): 737-744.
20. Machado RD, Pauciulo MW, Thomson JR et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 2001: 68(1): 92-102.
21. Lane KB, Machado RD, Pauciulo MW et al. Heterozygous germline mutations in BMPR2, encoding a TGF-b receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 2000: 26(1): 81-84.
22. Beppu H, Ichinose F, Kawai N et al. BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia. Am J Physiol Lung Cell Mol Physiol 2004: 287: L1241-L1247.
23. Machado RD, James V, Southwood M et al. Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension. Circulation 2005: 111: 607-613.
24. Yuan JX, Rubin LJ. Pathogenesis of pulmonary arterial hypertension: The need for multiple hits. Circulation 2005: 111: 534-538.